glp-1/fgf21 agonist boehringer A novel dual ZT003 has therapeutic potential for obesity, MASH and SHTG Transforming obesity: The advancement of
Description
Compound 28 demonstrated exceptional in vivo potency, with an IC 50 of 4.2 nM, alongside a favorable safety profile, making it a promising candidate for further preclinical research
Orforglipron had a similar safety profile as other GLP-1 receptor agonists. Trial outcomes For ATTAIN-2, researchers enrolled 1,613 adults aged 18 years and older with obesity or overweight plus one weight-related comorbidity, and with type 2 diabetes with an HbA1c between 7% and 10% at baseline (mean age, 56.8 years
Semaglutide is the seventh GLP-1 receptor agonist on the US market and the third dosed once weekly
The GIP component may also help preserve lean mass through its effects on insulin sensitivity in muscle tissue
J Clin Endocrinol Metab 2017
The field is moving quickly, and the clinical frameworks around these medications are still maturing
